Larroche C, Cacoub P, Godeau P
Service de médecine interne, hôpital de la Pitié-Salpêtrière, Paris, France.
Rev Med Interne. 1996;17(12):1003-13. doi: 10.1016/s0248-8663(97)80844-2.
Castleman's disease, also called angiofollicular lymph node hyperplasia was first described as a distinct entity by Castleman et al in 1956. Two forms are now described a localized and a multicentric. The clinical and biological signs are varied and heterogeneous, and the diagnostic is made on the histologic examination. This atypical lymphoproliferative disorder is of unknown origin, but interleukin 6 play a central part in this disease. Despite the benignity of this "prelymphoma state", an aggressive course with poor prognosis occur usually in the multicentric form. Malignant lymphomas and Kaposi's sarcoma have been associated with Castleman's disease.
卡斯特leman病，也称为血管滤泡性淋巴结增生，于1956年由卡斯特leman等人首次描述为一种独特的疾病实体。现在描述了两种形式，局限性和多中心性。临床和生物学体征多样且异质性，诊断基于组织学检查。这种非典型淋巴增殖性疾病起源不明，但白细胞介素6在该疾病中起核心作用。尽管这种“淋巴瘤前期状态”为良性，但多中心形式通常会出现侵袭性病程且预后不良。恶性淋巴瘤和卡波西肉瘤与卡斯特leman病有关。
